| A. Study cohort | B. No progress in CDR | C. No amyloid or tau pathology | D. No vascular pathology | E. No measurable in vivo pathology |
---|---|---|---|---|---|
Participants, N | 297 | 278 | 223 | 161 | 120 |
MMSE score, mean (SD)a | 29.1 (0.9) | 29.1 (0.9) | 29.1 (0.9) | 29.1 (0.9) | 29.1 (0.9) |
Age, mean (SD) | 73.5 (5.0) | 73.4 (5.0) | 73.4 (5.0) | 72.5 (4.6) | 72.2 (4.6) |
Education years, mean (SD) | 12.3 (3.7) | 12.3 (3.8) | 12.2 (3.6) | 12.5 (0.9) | 12.6 (3.5) |
Gender | |||||
 Male | 39.4% | 38.8% | 39.5% | 41.6% | 42.5% |
 Female | 60.6% | 61.2% | 60.5% | 58.4% | 57.5% |
APOE ε4 (≥ 1 allele) | 27.3% | 25.9% | 16.3% | 30.8% | 20.3% |
Prevalence of abnormal biomarkers | |||||
 CSF Aβ42/40 < 0.059 | 24.9% | 23.0% | 0% | 24.2% | 0% |
 CSF P-tau > 28 pg/mL | 15.2% | 13.3% | 0% | 14.3% | 0% |
 Log CSF NfL > 3.33 pg/mL | 2.4% | 1.8% | 2.2% | 1.2% | 0% |
 White matter lesionsb | 45.5% | 43.9% | 44.8% | 0% | 0% |
≥ 1 Cortical infarctions | 1.3% | 1.1% | 1.7% | 0% | 0% |
Comorbidity | |||||
 Hypertension | 43.4% | 42.8% | 43.5% | 41.0% | 43.3% |
 Diabetes | 10.1% | 10.4% | 9.4% | 11.2% | 10.0% |
 Ischemic heart disease | 6.7% | 6.8% | 6.3% | 4.3% | 2.5% |